Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757802 | 0.76 | — | — | |
| SCHEMBL7352569 | 0.70 | TSHR (0.32) | TSHR | |
| SCHEMBL4488551 | 0.67 | ALDH1A1 (0.50) | TSHRSIGMAR1HTR2CRYR2KDM4E | |
| SCHEMBL519685 | 0.64 | TSHR (0.53) | NOS3NOS2TSHRHTR2CMAOA | |
| SCHEMBL45328 | 0.64 | RYR2 (0.31) | RYR2KDM4EALDH1A1HPGD | |
| SCHEMBL3081411 | 0.64 | ALDH1A1 (0.38) | RYR2KDM4EALDH1A1HPGDMAOA | |
| SCHEMBL8275 | 0.64 | RYR2 (0.31) | RYR2KDM4EALDH1A1HPGD | |
| SCHEMBL1588593 | 0.64 | CA12 (0.35) | TSHRHTR2CRYR2KDM4EALDH1A1 | |
| SCHEMBL4495800 | 0.64 | TSHR (0.52) | TSHRSIGMAR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL29387129 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757582-B1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-30 | — | — | EP | claimed |
| US-8778628-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-15 | — | — | US | claimed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | claimed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | claimed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | claimed |
| EP-1757582-A1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-28 | — | — | EP | claimed |
| CN-115210273-B | Process for controlling the formation of ziegler-natta procatalyst particles and use for olefin polymerization | 布拉斯科美国公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240174776-A1 | SPHERICAL CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION | W.R. GRACE & CO.-CONN. (US) | 2024-05-30 | — | — | US | disclosed |
| US-11925689-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | SERINA THERAPEUTICS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20240043446-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | INTERVET INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20240043385-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE | INTERVET INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4308615-A1 | SPHERICAL CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION | W. R. Grace & Co.-Conn (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355546-A | Spherical catalyst component for olefin polymerization | 格雷斯公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2002018383-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| US-5968985-A | INHIBITORS OF SODIUM ION/HYDROGEN ION EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0773927-A2 | BENZOYLGUANIDINE DERIVATIVES AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1996004241-A2 | BENZOYLGUANIDINE DERIVATIVES AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | disclosed |
| EP-0639182-A1 | QUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-02-22 | — | — | EP | disclosed |
| WO-1992018483-A1 | QUINOLINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043385-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE | HRH4, PNPO, NME4 | NOS3 2931/4885NOS2 2849/4885TSHR 4610/4885 |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | NAT1, INMT, ARSA | NOS3 3755/4885NOS2 2463/4885TSHR 1304/4885 |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | NOS3 1915/4885NOS2 1807/4885TSHR 126/4885 |
| US-20240043446-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | DHODH, NISCH, DDT | NOS3 3049/4885NOS2 2469/4885TSHR 2866/4885 |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | CASR, CNR1, CNR2 | NOS3 1915/4885NOS2 1807/4885TSHR 126/4885 |
| US-11925689-B2 | Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same | ERBB3, ERBB2, PANK2 | NOS3 559/4885NOS2 1225/4885TSHR 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.